Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

By J. Valle, H. Wasan, D. Palmer, D. Cunningham, A. Anthoney, A. Maraveyas, S. Madhusudan, T. Iveson, S. Hughes, S. Pereira and 2 more. New England Journal of Medicine, 2010

3,744 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/0bdef4bfb8f9c0f0dcbe0be51e9934eea0a7fbc3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Lewis R. Roberts
2. Jordi Bruix1 , 2
3. G. Gores
4. Sumit Ghosh

In Pulmonary and Respiratory Medicine

1. Sumera I. Ilyas
2. G. Gores
3. Sumit Ghosh

In Surgery

1. Sumera I. Ilyas
2. Jordi Bruix1 , 2
3. G. Gores

Citations in the corpus

• Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. (2012, background): “Even with combination cytotoxic chemotherapy, the prognosis for patients remains poor and the median survival duration is 1 year [12].”
• Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma (2013, background): “The standard practice of care for advanced-stage iCCA is systemic chemotherapy with gemcitabine and cisplatin.(141)”
• Cisplatin: The first metal based anticancer drug. (2019, background): “For biliary cancer patients combination of cisplatin and gemcitabine is a good option [160].”
• Cholangiocarcinoma 2020: the next horizon in mechanisms and management (2020, positive): “The ABC-02 trial randomly assigned 410 patients with ECOG-PS ≤2 to systemic chemotherapy with gemcitabine alone or cisplatin–gemcitabine 336 ; the study showed an OS benefit in favour of cisplatin– gemcitabine (HR 0.64), a benefit confirmed in the Japanese randomized phase II BT22 study 337 .”
• Cholangiocarcinoma — evolving concepts and therapeutic strategies (2017, neutral): “For patients with advanced­stage or un ­ resectable cholangiocarcinoma, the available systemic therapies are of limited effectiveness: the median overall survival with the current standard­of­care chemo therapy regimen (gemcitabine and cisplatin) is 1 year 11 .”